Mark Chao, M.D., Ph.D.

Mark Chao is a physician-scientist and biotech entrepreneur with over 20 years of experience in oncology research. He is currently Chief Medical Officer of Scorpion Therapeutics, a clinical stage precision oncology therapeutics company. He was previously co-founder and CEO of TenSixteen Bio, a precision genomics therapeutics company. Prior to that, he served as VP in oncology clinical research at Gilead Sciences focused on early and late stage clinical development. Prior to that, he was co-founder and SVP of clinical development at Forty Seven, Inc., a clinical stage immuno-oncology which was acquired by Gilead Sciences for $4.9B in 2020. Mark was one of the scientific pioneers that discovered CD47, an anti-phagocytic signal, as a therapeutic target in oncology and helped lead clinical development from early to late stage development for a first-in-class CD47-targeting therapy.

He received his Ph.D. in cancer biology, M.D., internal medicine and hematology training at Stanford University. In 2021 he was named one of the 20(+1) under 40 next generation of biotech leaders by Endpoints News. He also serves on the scientific advisory board of IconOVir Bio and on the board of directors of the Northern California chapter of the Leukemia and Lymphoma Society, the Stanford Medicine Alumni Association and the AP Giannini Foundation.